Kantum Pharma is a privately-held biopharmaceutical company focused on developing therapies to prevent or reduce inflammaton initiated through the uridine diphosphate (UDP)-glucose/P2Y14 purinergic receptor signaling pathway in organs such as the kidneys, lungs and female reproductive tract.  The Company’s initial small molecule therapeutic program, KB-1801, has been shown preclinically to reduce renal inflammation and has the potential to transform the treatment paradigm for acute kidney injury AKI.  Kantum is pursuing additional applications of this technology for therapeutics and diagnostics to ameliorate the impact of numerous inflammatory disorders.

Acute kidney injury (AKI) is characterized by an abrupt loss of kidney function—this common medical complication affects 4,000,000 and kills 300,000 people every year in the US alone. AKI affects one in five hospitalized adults and one in three hospitalized children, and is associated with annual healthcare costs in the USA exceeding $10B. AKI occurs in roughly 30% of all cardiac surgeries, and Kantum Pharma is uniquely positioned to develop a novel specific AKI therapeutic to reduce its incidence, severity and sequelae.  In parallel, Kantum will develop a test to enable doctors to diagnose AKI before it develops. This combination of early diagnosis and specific therapy to reduce or prevent AKI incidence and progression promises to transform clinical outcomes for patients undergoing cardiac surgery.